drugset
Drugs / HG202
last change Jun 2026 re-read 3 minutes ago

HG202

CRISPR / gene editing targets VEGFA via inhibition

Developed for
wet macular degeneration
Investigated by
HuidaGene Therapeutics Co., Ltd. · Eye & ENT Hospital of Fudan University · Tianjin Medical University Eye Hospital

Trials 2

today NCT06623279 · Ph 1 NCT06031727 · Ph 0
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06031727 Sep 2023 → Jun 2025 overdue wet macular degeneration HuidaGene Therapeutics Co., Ltd. Recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT06623279 Apr 2025 → Feb 2027 expected wet macular degeneration HuidaGene Therapeutics Co., Ltd. Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2024-11-04 HuidaGene Therapeutics Co., Ltd. Regulatory HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration huidagene.com ↗
HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company developing genome medicines, today announced that the US FDA has cleared its HG202 investigational new drug (IND) application for neovascular age-related macular degeneration (nAMD).

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HG202 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06031727 ↗
1

NCT06623279 ↗
Action Inhibit “partially knock-down the expression of VEGFA” NCT06031727 ↗
Modality CRISPR / gene editing “CRISPR/Cas13 RNA-editing therapy” NCT06031727 ↗
Route Other “Once unilateral subretinal injection” NCT06031727 ↗
Target VEGFA “partially knock-down the expression of VEGFA” NCT06031727 ↗